- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Current Guidelines & Unmet Needs In The Treatment Of Agitation Associated With Alzheimer’s Dementia

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Current Guidelines & Unmet Needs In The Treatment Of Agitation Associated With Alzheimer’s Dementia
This is a Virtual Event for PsychU members in DC, Maryland and Virginia.
Individualized and multimodal treatment plans are recommended for patients with Alzheimer’s disease and Agitation associated with Alzheimer’s Dementia (AAD). There is a need for better identification of AAD. There is also a need for approved pharmacological treatments that have proven and favorable benefit, risk profiles to reduce symptoms and ultimately improve burden to caregivers and healthcare.
In this discussion, current treatment guidelines, assess risk/benefit profile, and discuss unmet needs of AAD treatment will be reviewed.

Dennis Sholler, PhD (OPDC)
Senior Medical Science Liaison, CNS

Justin Wimmer, PharmD
Medical Science Liaison
Speakers Dennis Sholler, PhD and Justin Wimmer, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)